Skip to main content
Equibles
RXRX logo

RXRX · Recursion Pharmaceuticals, Inc. · Analyst Estimates

Track RXRX — free

Use RXRX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RXRX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.82 +0.12 (+3.27%)
Russell 2000 member Rebalance outlook locked
Market Cap
$1.98B
Shares
535.34M
Volume · Oct 26 11.77M Avg daily vol (3M) 21.75M

Analyst Estimates

Compare analyst forecasts for Recursion Pharmaceuticals, Inc. across metrics and forecast periods.

Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.

Compiled consensus

These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.

Captured 2026-10-16 22:37 UTC · Publication dates shown per estimate · 8 metric / period groups

FY ending 2026-12-31

Analyst estimates for FY ending 2026-12-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
-0.99
-0.93
-0.87
7
-0.93
-0.92
-0.92
-0.92
1
1
0
0
Revenue
USD
Publication date not stated
29.00M
41.78M
72.00M
8
 — — — — — — — —

FY ending 2027-12-31

Analyst estimates for FY ending 2027-12-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
-1.04
-0.87
-0.68
7
-0.90
-0.89
-0.88
-0.94
1
1
0
0
Revenue
USD
Publication date not stated
20.70M
53.03M
110.00M
8
 — — — — — — — —

Q ending 2026-09-30

Analyst estimates for Q ending 2026-09-30
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
-0.25
-0.23
-0.20
6
-0.23
-0.23
-0.23
-0.23
1
1
0
0
Revenue
USD
Publication date not stated
8.28M
14.81M
30.20M
7
 — — — — — — — —

Q ending 2026-12-31

Analyst estimates for Q ending 2026-12-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
-0.27
-0.22
-0.18
6
-0.23
-0.22
-0.21
-0.22
1
1
0
0
Revenue
USD
Publication date not stated
6.58M
14.76M
30.20M
6
 — — — — — — — —
Key facts CIK 1601830 CUSIP 75629V104 13F (30d) 52 filings 52 filers Visit website Investor relations